Invectys Therapeutics
Invectys is a biopharmaceutical company founded in 2010 out of the Pasteur Institute, focused on developing innovative immunotherapy approaches to treat cancer. With headquarters in Houston, Texas, and a research & innovation center in Paris, Invectys exploits novel platforms such as HLA-G, a powerful immune checkpoint and tumor-specific antigen, and telomerase (TERT), a universal tumor antigen. The company's mission is to mobilize and restore the anti-tumor capacity of the immune system to target virtually all cancers.
Industries
Nr. of Employees
small (1-50)
Invectys Therapeutics
Products
Engineered CAR-T cell therapy targeting an immune checkpoint/tumor-specific antigen
Lead engineered CAR-T program directed at a tumor-expressed immune checkpoint antigen with preclinical in vivo efficacy and progression into first-in-human Phase 1/2a studies; received regulatory interactions including IND clearance and expedited designation.
IVS-3001
First-in-class 3rd-generation anti-HLA-G CAR-T cells designed to target and kill HLA-G-bearing cancer cells in advanced carcinoma.
Engineered CAR-T cell therapy targeting an immune checkpoint/tumor-specific antigen
Lead engineered CAR-T program directed at a tumor-expressed immune checkpoint antigen with preclinical in vivo efficacy and progression into first-in-human Phase 1/2a studies; received regulatory interactions including IND clearance and expedited designation.
IVS-3001
First-in-class 3rd-generation anti-HLA-G CAR-T cells designed to target and kill HLA-G-bearing cancer cells in advanced carcinoma.
Services
Design and execution of preclinical studies, including in vivo efficacy testing for cell therapy candidates.
Clinical protocol development and initiation support for Phase 1/2a oncology trials.
Creating and managing partnerships with clinical research centers and manufacturing organizations to advance cell therapy programs.
Design and execution of preclinical studies, including in vivo efficacy testing for cell therapy candidates.
Clinical protocol development and initiation support for Phase 1/2a oncology trials.
Creating and managing partnerships with clinical research centers and manufacturing organizations to advance cell therapy programs.
Expertise Areas
- CAR-T cell therapy development
- Immune checkpoint targeting (HLA-G-focused)
- Tumor antigen platform development (TERT)
- Early-phase oncology clinical trial management
Key Technologies
- CAR-T cell engineering
- Immune checkpoint-targeted immunotherapy
- Telomerase (TERT)-based antigen targeting
- Nanoparticle delivery systems
News & Updates
Invectys' CAR-T cell immunotherapy targeting HLA-G has been granted Fast Track designation by the FDA.
The company has initiated a clinical trial of its lead CAR-T program, IVS-3001, in solid tumors, and appointed Dr. Jake Kushner as its new CEO.
Invectys was awarded the 2023 Best Translational Development by the MATWIN international Board.
Invectys' CAR-T cell immunotherapy targeting HLA-G has been granted Fast Track designation by the FDA.
The company has initiated a clinical trial of its lead CAR-T program, IVS-3001, in solid tumors, and appointed Dr. Jake Kushner as its new CEO.
Invectys was awarded the 2023 Best Translational Development by the MATWIN international Board.